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INTRODUCTION: The most common cause of hyperthyroidism in children is graves’ disease – an autoim-
mune disorder in which antibodies stimulate the thyrotropin receptor to signal growth thyroid gland by
increasing thyroid hormone synthesis and release. It can be treated with medical therapy, radioactive
iodine, or surgery.
PRESENTATION OF CASE: JD was a two year oldmale who presentedwith severe diarrhea and diffuse neck
enlargement. Laboratory work up was consistent with graves’ disease.
DISCUSSION: Despite maximal outpatient and inpatient treatment with methimazole, atenolol, pred-
nisone, and SSKI, he suffered persistent thyrotoxicosis. He underwent near-total thyroidectomy without
complication.
CONCLUSION: This case is notable as it may represent the youngest patient in the literature who has
undergone thyroidectomy for graves’ disease.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
The most common cause of hyperthyroidism in children is
graves’ disease - an autoimmune disorder in which antibodies
stimulate the thyrotropin receptor to signal growth thyroid gland
by increasing thyroid hormone synthesis and release. It can be
treated with medical therapy, radioactive iodine, or surgery. Thy-
roidectomy is not often employed as a therapy in graves’ disease.
We present the case of a two-year old male with graves’ disor-
der unresponsive to medical therapy who underwent near total
thyroidectomy, whom we believe to be the youngest patient to
undergo thyroidectomy for graves’.
The estimated prevalence of graves’ in children ranges between
1 and 20 in 100,000 [1,2]. Manifestations of the disease mimic that
of adults, with a few key differences. graves’ in children nearly
always presents with a goiter [3]. Ophthalmopathy is more com-
mon than in adults but less severe; rarely is dermopathy or atrial
ﬁbrillation seen in children [4].
Graves’ can affect growth and puberty in children by delaying
its onset or slowing its progression. It can lead to increased height
and advancement of bone age [5]. Weight loss is a common char-
acteristic resulting from thyroid-induced calorigenesis as well as
malabsorption secondary to increased gut motility.
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Most children with graves’ have a family history of hyper-
thyroidism. Twin studies’ have demonstrated that 80% of the
risk of graves’ in children can be attributed to genetics. There
is an increased prevalence of co-existing autoimmune disorders,
including celiac disease and myasthenia gravis. Blood tests may
demonstrate a positive ANCA titer [6]. Associations exist with
non-autoimmune disorders, includingDown Syndrome and Turner
Syndrome [7].
Other causes of hyperthyroidism in children include toxic
multi-nodular goiter, toxic adenoma, Hashitoxicosis, and subacute
thyroiditis. Diagnosis of graves’ can bemade by serum detection of
thyrotropin-receptor antibodies, found in 60–90% of children with
graves’ [8].
2. Case presentation
In April of 2011, JD presented to his pediatrician as a two-
and-a-half-year old male with severe diarrhea and diffuse neck
enlargement. His mother complained that he had increasing
hyperactivity, insomnia, diaphoresis, and tachycardia. Laboratory
evaluation was consistent with graves’ disease, with an unde-
tectable TSH, a total T4 level of 31.2mcg/dL, and a TSI of 407% the
normal value.Hewas started onmethimazole, atenolol, prednisone
and saturated solution of potassium iodide (SSKI). He contin-
ued to have symptoms, despite outpatient management involving
increasing doses of this regimen, with diarrhea being the most
persistent.
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Table 1
Lab values upon presentation May 3, 2011.
Normal values JD
Free T4 (Thyroxine) 0.9–1.7ng/dL 5.49
Estimated FTI 6.0–10.5 27.4
Thyroglobulin Ab Negative 160
TPO Ab Negative >20480
TSH (Thyrotropin) 0.3–4.0mcU/mL <0.01
T3 (Tri-iodothyrine) 80–195ng/dL 597
T4 (Thyroxine) 5.0–11.6mcg/dL 19.2
He was born full-term without complications in his medical or
developmentalhistoryuntilApril 2011.Hewalkedat ageone, spoke
intelligibly at age 15 months, and was able to speak three-word
sentenceswith an adequate vocabulary at age two. Hismother was
diagnosed with graves’ disease at age eight, which was active until
age 13 and then quiescent until 2006, three years prior to JD’s birth.
She was taking propylthiouracil at the time of JD’s birth, with nor-
mal thyroid levels throughout pregnancy. Therewas no evidence of
neonatal thyrotoxicosis. JD’s family history was also signiﬁcant for
a paternal grandmother andpaternal auntwith unspeciﬁed thyroid
disorders. There were no other known autoimmune diseases in his
family.
In late April 2011, JD was admitted to a local hospital for sta-
bilization of his cardiac and thyroid function. While inpatient, his
dose ofmethimazolewas increased; atenolol, prednisone, and SSKI
doses were maintained. He was transferred to the University of
Chicago on May 3, 2011, for persistent thyrotoxicosis. Table 1 lists
his laboratory data upon presentation. Workup demonstrated a
concurrent rotavirus infection; he was treated with resuscitative
intravenous ﬂuids and discharged on hospital day two with pedi-
atric endocrinology follow-up.
The symptoms of dry skin, diarrhea, and tachycardia had
persisted despite maximal outpatient and inpatient medical man-
agement. Because of his intractable symptoms, his pediatric
endocrinologist referred him for surgical management.
In June 2011, JD was pre-admitted the evening prior to surgery.
He received pre-operative stress dose steroids because of his pred-
nisone usage. Under general anesthesia, he underwent a near-total
thyroidectomy. Estimated blood loss was ten milliliters; a subcu-
taneous Jackson-Pratt drain was left in the surgical ﬁeld. He was
admitted to the Pediatric Intensive Care Unit overnight. On post-
operative day one, the drain was removed. He was discharged on
a steroid taper on post-operative day three after an uncomplicated
hospital course. Final pathologydemonstrated27gof thyroid tissue
consistent with treated graves’ disease.
He was seen in post-operative clinic two weeks later. His
symptoms of diarrhea and tachycardia had resolved and he was
tolerating his steroid taper. The incision was healing well without
signs of infection. His post-operative calcium levels never altered.
He was started on levothyroxine.
Onemonth after surgery, JD demonstrated symptoms and labo-
ratory evidence consistentwith hypothyroidism.His levothyroxine
was increased by his pediatric endocrinologist. Approximately
six months after surgery, his laboratory values normalized with
levothyroxine.
3. Conclusion
This case is notable as it represents the youngest patient in
the literature who has undergone thyroidectomy for graves’ dis-
ease. After medical management was insufﬁcient to control JD’s
symptoms, othermodalitieswere considered. Because of his young
age, radioactive iodine was ruled out as a possibility. The risks and
beneﬁts of surgery were discussed with his family. Near-total thy-
roidectomy was successful in palliating his symptoms.
Treatment modalities for graves’ mirror those of the treatment
of adults and can be divided into three categories:medical therapy,
radioactive iodine, and surgery.
Initial medical therapy most often consists of methimazole
or propylthiouracil. These drugs offer a chance of permanent
remission at a lower cost than the other modalities. However,
anti-thyroid medications have side effects including cutaneous
symptoms (rash, hives), arthralgias, and gastrointestinal symp-
toms; rarer but more serious side effects include hepatotoxicity,
granulocytopenia, and vasculitis. Further symptom management
cannecessitateusageofbetablockers; atenolol is preferredbecause
of its lower risk of bronchospasm. Whereas all three modalities
require routine monitoring, surveillance is more intensive with
medical therapy.
The majority of pediatric endocrinologists recommend medical
therapy as an initial treatment. Methimazole is preferred to propy-
lthiouracil for its lower side effect proﬁle, especially with respect
to hepatotoxicity [9]. 87–100% of children become euthyroid in a
period of weeks to months. The intention of treatment is to render
the patient euthyroid and then wean the anti-thyroid medication.
A recent trial demonstrated a total of 50% in remission at 4.5 years
[10].
Radioactive iodine is delivered in oral form; it can offer perma-
nent cure of hyperthyroidism. However, each treatment requires
radiation precautions for up to a week afterwards. Exposing young
children to radiation raises concerns for resultant cancer, often
leading parents of patients and physicians away from this treat-
ment modality. Radioactive iodine has traditionally been reserved
for childrenwho suffer side effects frommedical therapy; recently,
however, its usage as a ﬁrst line therapy has increased.
Surgery offers a timely andpermanent cure for hyperthyroidism
but is most often regarded a second-line treatment modality after
medical therapy. The risks of surgery include hypothyroidism,
hypoparathyroidism secondary to parathyroid injury, recurrent
laryngeal nerve injury, infection, and the risk of bleeding and anes-
thesia. However, in experienced hands, thyroid surgery in children
has no greater risk than in adults. There is also substantial ini-
tial cost involved as compared with the other therapy modalities.
The most commonly performed operation is a near-total thy-
roidectomy, leaving minimal thyroid tissue to balance the risk of
persistent hyperthyroidism with permanent hypothyroidism.
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